Transscleral Photocoagulation to Treat ROP in Eyes with Media Opacity
نویسنده
چکیده
It has been well established that laser treatment for type 1 prethreshold retinopathy of prematurity is effective in approximately 90 percent of treated eyes, avoiding retinal detachment.1 Transpupillary laser therapy is certainly the standard; however, there are circumstances in which transpupillary treatment may be difficult or impossible to perform thus allowing progression of retinopathy of prematurity. Many years ago in the circumstance of media opacity, cryotherapy was used. Cryotherapy was shown to be effective in the CRYO-ROP study many years ago.2 However it led to effusive retinal detachment, which was rather a common problem following cryotherapy. The introduction of transscleral diode laser retinal photocoagulation allows treatment of the peripheral retina in the face of media opacity. Since transscleral diode laser treatment ablates the ciliary body, it must be applied very cautiously, especially in the face of media opacity, to avoid excessive ciliary destruction and hypotony. The use of transpupillary illumination to identify the position of the ciliary body can allow safer delivery of treatment to the peripheral retina. Transscleral retinal photocoagulation can allow time for resolution of vitreous hemorrhage followed by additional transpupillary laser application if needed. Certainly, transpupillary retinal photocoagulation with the indirect laser is the standard of care worldwide, but there are rare circumstances in which transscleral diode laser can be very helpful. As pointed out by Dr. Parvaresh et al, posterior disease is more effectively treated with transpupillary diode laser retinal photocoagulation.3 I do not think that transscleral diode laser retinal photocoagulation will in any way replace transpupillary treatment. However, it is important to realize that such a modality does exist and does not seem to cause effusive retinal detachments often seen following cryotherapy. I think the authors are to be congratulated for pursuing this type of therapeutic intervention which in some circumstances will lead to a good outcome, avoiding vitreous surgery for media opacity.
منابع مشابه
RETINOPATHY of PREMATURITY Transscleral Retinal Photocoagulation (TSRPC) Retinopathy of Prematurity Transscleral Retinal Photocoagulation (TSRPC)
Retinopathy of Prematurity Transscleral Retinal Photocoagulation (TSRPC) The 810 nm diode laser wavelength makes lens-sparing transscleral coagulation of the retina possible, and to evaluate the efficacy and safety of transscleral diode laser coagulation for threshold ROP, the authors performed a controlled clinical study. Forty eyes of 20 preterm infants (gestational age 24-29 weeks, mean 26.8...
متن کاملTransscleral Diode Laser Photocoagulation for Type 1 Prethreshold Retinopathy of Prematurity
PURPOSE To report the outcomes of transscleral diode laser photocoagulation for treatment of type 1 prethreshold retinopathy of prematurity (ROP). METHODS In this prospective interventional case series, 139 eyes of 73 infants with type 1 prethreshold ROP underwent transscleral diode laser photocoagulation of the avascular retina under topical anesthesia without making a conjunctival incision....
متن کاملنتایج ریفرکتیو و آناتومیک فتوکواگولاسیون با لیزر دیود در مبتلایان به رتینوپاتی ناشی از نارسی
Introduction & Objective: Retinopathy of prematurity (ROP) is a major cause of blindness in premature newborns. It accounts for 4% of childhood blindness in developed countries and up to 40% in developing countries. The aim of this study is to report the refractive and anatomical outcome of patients who had undergone laser photocoagulate on for retinopathy of prematurity (ROP). Materials & M...
متن کاملIntravitreal Injection of Bevacizumab for Retinopathy of Prematurity in an Infant with Peters Anomaly
PURPOSE To report our findings in an infant with Peters anomaly type II whose retinopathy of prematurity (ROP) was treated with an anti-VEGF agent and surgeries. CASE REPORT A male infant weighing 548 g was born prematurely at 23 weeks and 1 day with corneal opacity and shallow anterior chambers in both eyes. At the postmenstrual age of 35 weeks and 3 days, the infant was tentatively diagnose...
متن کاملAnti-vascular endothelial growth factor treatment for retinopathy of prematurity
Retinopathy of prematurity (ROP) is a proliferative disorder of the developing retina in premature and low birth weight infants. Recently, the role of vascular endothelial growth factor (VEGF) in the pathophysiology of ROP has been well studied and anti-VEGF drugs have been used in phase 2 to treat ROP patients in many ways. At first, ophthalmologists began to give intravitreal bevacizumab (IVB...
متن کامل